Max Macaluso, Ph.D. has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
May 15, 2013 at 9:13PM
Pharmaceutical giant Sanofi (NYSE:SNY) and biotech Regeneron (NASDAQ:REGN) have announced the start of two late-stage clinical trials for their experimental rheumatoid arthritis drug sarilumab. This antibody is being tested in combination with methotrexate, a drug often used for the treatment of rheumatoid arthritis, and will be compared to Amgen (NASDAQ:AMGN) and Pfizer's (NYSE:PFE) Enbrel. In the following video, health-care analyst Max Macaluso discusses these clinical trials and how this drug could compete in the rheumatoid arthritis market.
- May 15, 2013 at 9:13PM
- Health Care
- Finally! Canada's Recreational Marijuana Market Opens for Business
- 2 Big Pharmas Pleased With J&J's Third-Quarter Earnings Report
- Why Shopify, Fresenius Medical Care, and Tilray Slumped Today
- Healthcare Services Group, INC. (HCSG) Q3 Earnings Conference Call Transcript
- Is Tilray a Better Marijuana Stock to Buy Than Aurora Cannabis?